Wealth Enhancement Advisory Services
KRYS icon

Wealth Enhancement Advisory Services’s Krystal Biotech KRYS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
+651
New +$195K ﹤0.01% 3428

Other funds holding KRYS

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Wealth Enhancement Advisory Services's KRYS Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Krystal Biotech (KRYS) in Q2 2026: 651 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #3428 among its holdings.

74 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Wealth Enhancement Advisory Services held 651 shares of Krystal Biotech worth $238K as of Q2 2026.
  • Krystal Biotech was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3428 holding.
  • 74 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.